Latest Carboplatin Stories
CALGARY, March 24 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC, NASDAQ: ONCY) today announced that it has completed patient enrollment in its U.S.
CALGARY, March 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
CALGARY, Feb. 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
INDIANAPOLIS and PRINCETON, N.J., Feb.
HUNTSVILLE, Ala., Feb. 2, 2011 /PRNewswire/ -- EGEN, Inc. today announced that the Food and Drug Administration (FDA) has awarded the company a four-year grant of $1,600,000 to assist in the Phase II clinical development of EGEN-001, the company's lead product.
CALGARY, Jan. 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone.
BURLINGTON, Mass., Dec.
Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity.
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.
- totally perplexed and mixed up.